Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following technical, regulatory and commercial update on its SlimBiome® product platform.

Technical Update

OptiBiotix has developed an improved version of SlimBiome® using advanced processing technology which provides the following benefits:-

i. Creating a single homogenous product reducing component separation in transport and improving product consistency. This opens up new application opportunities in areas which lack the ability to blend or remix SlimBiome® (e.g. in store bakeries)

ii. Enhanced solubility giving better product presentation and greatly enhancing flavour and mouthfeel. This improves the taste and consumer experience of products containing SlimBiome® such as 'GoFigure®' shakes and bars

iii. Improved dispersion in water opening up new applications areas to meets demand for 'on the go' products

iv. Lower manufacturing costs due to less waste and more efficient production processes

Commercial and Regulatory Update

OptiBiotix has made significant progress developing and enhancing its pipeline of innovative products with a strong scientific and clinical evidence base. This has attracted commercial interest from a range of manufacturing, retail and corporate partners. Recent commercial developments include:-

i. The Company has obtained FDA registration for both its LP-LDL® and SlimBiome® product ranges allowing access to the US market

ii. The Company will be launching its improved version of SlimBiome® at Supply Side West and exhibiting with a potential joint development partner, Cereal Ingredients Inc from Kansas, USA. Cereal Ingredients is a privately held specialty ingredients manufacturer, dedicated to the development and manufacture of unique, high-quality products that contribute a meaningful point of difference. Cereal Ingredients are looking to incorporate SlimBiome® into their range of cereal based particulates and ingredients, aimed at the nutraceutical, health and wellbeing sectors of the industry.

Further product development is ongoing with a number of manufacturers, corporates and large retailers to extend SlimBiome®'s application into 'Health & Wellbeing' food and beverage products. This is to coincide with increased consumer awareness of using functional natural ingredients as part of a healthy lifestyle to manage and reduce the risks of illness and disease.

Stephen O'Hara, CEO of OptiBiotix, commented: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners. This announcement updates investors on the technical and commercial progress of our SlimBiome® product platform, building on its proven science and consumer efficacy in GoFigure® products. As we build the range of applications, products and geographic scope of SlimBiome® with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following technical, regulatory and commercial update on its SlimBiome® product platform.

Technical Update

OptiBiotix has developed an improved version of SlimBiome® using advanced processing technology which provides the following benefits:-

i. Creating a single homogenous product reducing component separation in transport and improving product consistency. This opens up new application opportunities in areas which lack the ability to blend or remix SlimBiome® (e.g. in store bakeries)

ii. Enhanced solubility giving better product presentation and greatly enhancing flavour and mouthfeel. This improves the taste and consumer experience of products containing SlimBiome® such as 'GoFigure®' shakes and bars

iii. Improved dispersion in water opening up new applications areas to meets demand for 'on the go' products

iv. Lower manufacturing costs due to less waste and more efficient production processes

Commercial and Regulatory Update

OptiBiotix has made significant progress developing and enhancing its pipeline of innovative products with a strong scientific and clinical evidence base. This has attracted commercial interest from a range of manufacturing, retail and corporate partners. Recent commercial developments include:-

i. The Company has obtained FDA registration for both its LP-LDL® and SlimBiome® product ranges allowing access to the US market

ii. The Company will be launching its improved version of SlimBiome® at Supply Side West and exhibiting with a potential joint development partner, Cereal Ingredients Inc from Kansas, USA. Cereal Ingredients is a privately held specialty ingredients manufacturer, dedicated to the development and manufacture of unique, high-quality products that contribute a meaningful point of difference. Cereal Ingredients are looking to incorporate SlimBiome® into their range of cereal based particulates and ingredients, aimed at the nutraceutical, health and wellbeing sectors of the industry.

Further product development is ongoing with a number of manufacturers, corporates and large retailers to extend SlimBiome®'s application into 'Health & Wellbeing' food and beverage products. This is to coincide with increased consumer awareness of using functional natural ingredients as part of a healthy lifestyle to manage and reduce the risks of illness and disease.

Stephen O'Hara, CEO of OptiBiotix, commented: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners. This announcement updates investors on the technical and commercial progress of our SlimBiome® product platform, building on its proven science and consumer efficacy in GoFigure® products. As we build the range of applications, products and geographic scope of SlimBiome® with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following technical, regulatory and commercial update on its SlimBiome® product platform.

Technical Update

OptiBiotix has developed an improved version of SlimBiome® using advanced processing technology which provides the following benefits:-

i. Creating a single homogenous product reducing component separation in transport and improving product consistency. This opens up new application opportunities in areas which lack the ability to blend or remix SlimBiome® (e.g. in store bakeries)

ii. Enhanced solubility giving better product presentation and greatly enhancing flavour and mouthfeel. This improves the taste and consumer experience of products containing SlimBiome® such as 'GoFigure®' shakes and bars

iii. Improved dispersion in water opening up new applications areas to meets demand for 'on the go' products

iv. Lower manufacturing costs due to less waste and more efficient production processes

Commercial and Regulatory Update

OptiBiotix has made significant progress developing and enhancing its pipeline of innovative products with a strong scientific and clinical evidence base. This has attracted commercial interest from a range of manufacturing, retail and corporate partners. Recent commercial developments include:-

i. The Company has obtained FDA registration for both its LP-LDL® and SlimBiome® product ranges allowing access to the US market

ii. The Company will be launching its improved version of SlimBiome® at Supply Side West and exhibiting with a potential joint development partner, Cereal Ingredients Inc from Kansas, USA. Cereal Ingredients is a privately held specialty ingredients manufacturer, dedicated to the development and manufacture of unique, high-quality products that contribute a meaningful point of difference. Cereal Ingredients are looking to incorporate SlimBiome® into their range of cereal based particulates and ingredients, aimed at the nutraceutical, health and wellbeing sectors of the industry.

Further product development is ongoing with a number of manufacturers, corporates and large retailers to extend SlimBiome®'s application into 'Health & Wellbeing' food and beverage products. This is to coincide with increased consumer awareness of using functional natural ingredients as part of a healthy lifestyle to manage and reduce the risks of illness and disease.

Stephen O'Hara, CEO of OptiBiotix, commented: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners. This announcement updates investors on the technical and commercial progress of our SlimBiome® product platform, building on its proven science and consumer efficacy in GoFigure® products. As we build the range of applications, products and geographic scope of SlimBiome® with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following technical, regulatory and commercial update on its SlimBiome® product platform.

Technical Update

OptiBiotix has developed an improved version of SlimBiome® using advanced processing technology which provides the following benefits:-

i. Creating a single homogenous product reducing component separation in transport and improving product consistency. This opens up new application opportunities in areas which lack the ability to blend or remix SlimBiome® (e.g. in store bakeries)

ii. Enhanced solubility giving better product presentation and greatly enhancing flavour and mouthfeel. This improves the taste and consumer experience of products containing SlimBiome® such as 'GoFigure®' shakes and bars

iii. Improved dispersion in water opening up new applications areas to meets demand for 'on the go' products

iv. Lower manufacturing costs due to less waste and more efficient production processes

Commercial and Regulatory Update

OptiBiotix has made significant progress developing and enhancing its pipeline of innovative products with a strong scientific and clinical evidence base. This has attracted commercial interest from a range of manufacturing, retail and corporate partners. Recent commercial developments include:-

i. The Company has obtained FDA registration for both its LP-LDL® and SlimBiome® product ranges allowing access to the US market

ii. The Company will be launching its improved version of SlimBiome® at Supply Side West and exhibiting with a potential joint development partner, Cereal Ingredients Inc from Kansas, USA. Cereal Ingredients is a privately held specialty ingredients manufacturer, dedicated to the development and manufacture of unique, high-quality products that contribute a meaningful point of difference. Cereal Ingredients are looking to incorporate SlimBiome® into their range of cereal based particulates and ingredients, aimed at the nutraceutical, health and wellbeing sectors of the industry.

Further product development is ongoing with a number of manufacturers, corporates and large retailers to extend SlimBiome®'s application into 'Health & Wellbeing' food and beverage products. This is to coincide with increased consumer awareness of using functional natural ingredients as part of a healthy lifestyle to manage and reduce the risks of illness and disease.

Stephen O'Hara, CEO of OptiBiotix, commented: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners. This announcement updates investors on the technical and commercial progress of our SlimBiome® product platform, building on its proven science and consumer efficacy in GoFigure® products. As we build the range of applications, products and geographic scope of SlimBiome® with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following technical, regulatory and commercial update on its SlimBiome® product platform.

Technical Update

OptiBiotix has developed an improved version of SlimBiome® using advanced processing technology which provides the following benefits:-

i. Creating a single homogenous product reducing component separation in transport and improving product consistency. This opens up new application opportunities in areas which lack the ability to blend or remix SlimBiome® (e.g. in store bakeries)

ii. Enhanced solubility giving better product presentation and greatly enhancing flavour and mouthfeel. This improves the taste and consumer experience of products containing SlimBiome® such as 'GoFigure®' shakes and bars

iii. Improved dispersion in water opening up new applications areas to meets demand for 'on the go' products

iv. Lower manufacturing costs due to less waste and more efficient production processes

Commercial and Regulatory Update

OptiBiotix has made significant progress developing and enhancing its pipeline of innovative products with a strong scientific and clinical evidence base. This has attracted commercial interest from a range of manufacturing, retail and corporate partners. Recent commercial developments include:-

i. The Company has obtained FDA registration for both its LP-LDL® and SlimBiome® product ranges allowing access to the US market

ii. The Company will be launching its improved version of SlimBiome® at Supply Side West and exhibiting with a potential joint development partner, Cereal Ingredients Inc from Kansas, USA. Cereal Ingredients is a privately held specialty ingredients manufacturer, dedicated to the development and manufacture of unique, high-quality products that contribute a meaningful point of difference. Cereal Ingredients are looking to incorporate SlimBiome® into their range of cereal based particulates and ingredients, aimed at the nutraceutical, health and wellbeing sectors of the industry.

Further product development is ongoing with a number of manufacturers, corporates and large retailers to extend SlimBiome®'s application into 'Health & Wellbeing' food and beverage products. This is to coincide with increased consumer awareness of using functional natural ingredients as part of a healthy lifestyle to manage and reduce the risks of illness and disease.

Stephen O'Hara, CEO of OptiBiotix, commented: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners. This announcement updates investors on the technical and commercial progress of our SlimBiome® product platform, building on its proven science and consumer efficacy in GoFigure® products. As we build the range of applications, products and geographic scope of SlimBiome® with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following technical, regulatory and commercial update on its SlimBiome® product platform.

Technical Update

OptiBiotix has developed an improved version of SlimBiome® using advanced processing technology which provides the following benefits:-

i. Creating a single homogenous product reducing component separation in transport and improving product consistency. This opens up new application opportunities in areas which lack the ability to blend or remix SlimBiome® (e.g. in store bakeries)

ii. Enhanced solubility giving better product presentation and greatly enhancing flavour and mouthfeel. This improves the taste and consumer experience of products containing SlimBiome® such as 'GoFigure®' shakes and bars

iii. Improved dispersion in water opening up new applications areas to meets demand for 'on the go' products

iv. Lower manufacturing costs due to less waste and more efficient production processes

Commercial and Regulatory Update

OptiBiotix has made significant progress developing and enhancing its pipeline of innovative products with a strong scientific and clinical evidence base. This has attracted commercial interest from a range of manufacturing, retail and corporate partners. Recent commercial developments include:-

i. The Company has obtained FDA registration for both its LP-LDL® and SlimBiome® product ranges allowing access to the US market

ii. The Company will be launching its improved version of SlimBiome® at Supply Side West and exhibiting with a potential joint development partner, Cereal Ingredients Inc from Kansas, USA. Cereal Ingredients is a privately held specialty ingredients manufacturer, dedicated to the development and manufacture of unique, high-quality products that contribute a meaningful point of difference. Cereal Ingredients are looking to incorporate SlimBiome® into their range of cereal based particulates and ingredients, aimed at the nutraceutical, health and wellbeing sectors of the industry.

Further product development is ongoing with a number of manufacturers, corporates and large retailers to extend SlimBiome®'s application into 'Health & Wellbeing' food and beverage products. This is to coincide with increased consumer awareness of using functional natural ingredients as part of a healthy lifestyle to manage and reduce the risks of illness and disease.

Stephen O'Hara, CEO of OptiBiotix, commented: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners. This announcement updates investors on the technical and commercial progress of our SlimBiome® product platform, building on its proven science and consumer efficacy in GoFigure® products. As we build the range of applications, products and geographic scope of SlimBiome® with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.